Inventor profile of:

Hoffmann-La Roche Inc.

City:

Country:

United States

Published Applications:

20

Last publication date:

2014-07-10

Top Assignees for applications by Hoffmann-La Roche Inc.

The entities that hold a legal rights for patent applications filed by inventor Hoffmann-La Roche Inc.:

Recent patent applications by Hoffmann-La Roche Inc.

Hoffmann-La Roche Inc. from , US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2014-07-10
US20140193397A1
Physics

METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY

#2 | 2014-03-20
US20140079706A1
Human necessities

COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF

#3 | 2014-03-13
US20140073567A1
Chemistry; metallurgy

USE OF PEGYLATED IGF-1 VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

#4 | 2014-03-06
US20140065707A1
Chemistry; metallurgy

Antibodies against human angiopoietin 2

#5 | 2014-02-13
US20140045742A1
Chemistry; metallurgy

Serpin-finger fusion polypeptide

#6 | 2014-02-06
US20140038210A1
Physics

ANTI-HUMAN IgG1 ANTIBODY

#7 | 2014-01-30
US20140032127A1
Physics

SPECTROSCOPIC FINGER-PRINTING OF RAW MATERIALS

#8 | 2014-01-16
US20140017232A1
Physics

METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY

#9 | 2014-01-16
US20140017231A1
Physics

METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY

#10 | 2014-01-02
US20140004104A1
Human necessities

COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT

#11 | 2013-12-19
US20130336960A1
Physics

Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

#12 | 2013-12-19
US20130336959A1
Physics

Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

#13 | 2013-08-29
US20130225588A1
Chemistry; metallurgy

Substituted naphthylacetic acids

#14 | 2013-08-22
US20130217713A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

#15 | 2013-08-22
US20130217712A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

#16 | 2013-08-22
US20130217665A1
Chemistry; metallurgy

Pyrrolidine derivatives

#17 | 2013-08-22
US20130217623A1
Human necessities

CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL)

#18 | 2013-08-15
US20130210843A1
Chemistry; metallurgy

Predictive marker for EGFR inhibitor treatment

#19 | 2013-08-15
US20130210799A1
Chemistry; metallurgy

Azetidine derivatives

#20 | 2013-08-15
US20130209478A1
Chemistry; metallurgy

FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN

InventorID:

388538 ⎘